Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Inzinger, M; Wippel-Slupetzky, K; Weger, W; Richter, L; Mlynek, A; Fleischander, B; Scheurecker, C; Sandor, N; Mairhofer, D; Sator, PG; Moser-Oberthaler, S; Häring, N; Viznerova, P; Painsi, C; Tanew, A; Ponholzer, P; Tatarski, R; Brenner, W; Stingl, G; Salmhofer, W; Rappersberger, K; Klein, G; Saxinger, W; Auböck, J; Kölli, C; Trautinger, F; Steiner, A; Ratzinger, G; Strohal, R; Riedl, E; Lange-Asschenfeldt, B; Pehamberger, H; Volc-Platzer, B; Selhofer, S; Legat, FJ; Müllegger, R; Reider, N; Schmuth, M; Hintner, H; Hofer, A; Gruber-Wackernagel, A; Aberer, W; Quehenberger, F; Wolf, P.
Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria.
Acta Derm Venereol. 2016; 96(2):207-212 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Aberer Werner
Gruber-Wackernagel Alexandra
Hofer Angelika
Inzinger Martin
Legat Franz
Müllegger Robert
Painsi Clemens
Quehenberger Franz
Salmhofer Wolfgang
Weger Wolfgang
Wolf Peter

Dimensions Citations:

Plum Analytics:
This retrospective multicentre analysis from the Psoriasis Registry Austria (PsoRA) was conducted to determine drug effectiveness and survival of anti-tumour necrosis factor alpha (anti-TNF-α) agents in patients with moderate-to-severe chronic plaque psoriasis over a 9-year period. Data on 1,019 treatment cycles with adalimumab (n = 460), etanercept (n = 501), and/or infliximab (n = 58) administered to 827 patients (272 women, 555 men) were available for analysis. Compared with etanercept, adalimumab and infliximab showed superior short-term effectiveness. Intention-to-treat-calculated median drug survivals for adalimumab (1,264 days) and etanercept (1,438 days) were similar to each other (p = 0.74), but significantly superior to that of infliximab (477 days) (p = 7.0e-07 vs. adalimumab and p=2.2e-07 vs. etanercept, respectively). Their drug survival rates at 36 months were 51.6%, 56.0%, and 22.6%, respectively. Survival rates correlated significantly with effectiveness for adalimumab and etanercept, but not for infliximab.
Find related publications in this database (using NLM MeSH Indexing)
Activities of Daily Living -
Adolescent -
Adult -
Aged -
Aged, 80 and over -
Austria -
Biological Products - adverse effects
Biological Products - therapeutic use
Female -
Humans -
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - therapeutic use
Intention to Treat Analysis -
Kaplan-Meier Estimate -
Male -
Middle Aged -
Proportional Hazards Models -
Psoriasis - diagnosis
Psoriasis - drug therapy
Psoriasis - immunology
Registries -
Retrospective Studies -
Severity of Illness Index -
Time Factors -
Treatment Outcome -
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor Necrosis Factor-alpha - immunology
Young Adult -

Find related publications in this database (Keywords)
drug survival
daily life conditions
© Med Uni Graz Impressum